CORCEPT THERAPEUTICS INC

CORTNASDAQ

🏆 #768 by market capUS Equity

$114.81▼ $0.71 (−0.62%)

After hours · at close

🔔

Track CORT

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 0.6%

7d▼ 2.3%

14d▲ 3.6%

30d▲ 0.8%

ytd▲ 230.0%

1y▲ 36.9%

🏦Market Cap

$12.41B

Mid Cap

📈Revenue Growth (YoY)

+16.0%

Healthy

📊Gross Margin

98.3%

High

💵FCF Margin

14.9%

Healthy

⚖️P/S Ratio

15.0x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $113.87 – $116.12
52-Week Range: $28.66 – $126.38
Volume: $3.47B
Avg Volume: $4.28B
Shares Outstanding: 108.1M
Next Earnings: Nov 24, 2026

Fundamentals Snapshot

Annual Revenue: $834M
Last Q Revenue: $202M
P/E Ratio: 225.6
P/S Ratio: 15.0x
EPS (TTM): $0.43
Dividend Yield: —
Dilution (1yr): +1.2%

Why Investors Own CORT

✓High-growth profile — revenue up +14.5% YoY with expanding US Equity exposure.
✓Healthy economics — 26% gross margin and 25% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CORCEPT THERAPEUTICS INC

CORT

Financial Trends

Revenue

$761M▲ +12.8% YoY

Gross Margin

98.3%▼ −0.1% YoY

Operating Income

$45M▼ −67.3% YoY

Free Cash Flow

$142M▼ −27.6% YoY

Shares Outstanding

119.9M▲ +1.2% YoY

Net Cash

$114M▼ −$6M YoY

StockOtter · stockotter.space

About CORCEPT THERAPEUTICS INC

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

🦦